When was Anthos Therapeutics founded?

Anthos Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Anthos Therapeutics located?

Anthos Therapeutics is headquartered in Cambridge, United States.

Who is the current CEO of Anthos Therapeutics?

Bill Meury of Anthos Therapeutics.

How many employees does Anthos Therapeutics have?

As of Mar 18, 2025, the latest employee count at Anthos Therapeutics is 60.

Is Anthos Therapeutics a funded company?

Anthos Therapeutics is a funded company, having raised a total of $250M in its 1st and only funding round, a PE round on Feb 28, 2019.

How much is Anthos Therapeutics worth?

The last known valuation of Anthos Therapeutics was $3.1B as of Feb 11, 2025.

When was the latest funding round of Anthos Therapeutics?

Anthos Therapeutics' latest funding was a $250M PE round on Feb 28, 2019, with participation from 2 investors.

Is Anthos Therapeutics a Cardiac and Vascular Disorders company?

The primary sectors of Anthos Therapeutics are Cardiac and Vascular Disorders, Hematology and Immunotherapy.

Where does Anthos Therapeutics rank among its competitors?

Anthos Therapeutics ranks 46th amongst 220 active competitors, of which 71 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was IgGenix, which secured $40M in Feb, 2023.

Who are the top competitors of Anthos Therapeutics?

Anthos Therapeutics' top competitors include argenx, Alexion and Halozyme. Among them, IgGenix secured the most recent funding round in February, 2023.

Anthos Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Anthos Therapeutics is an acquired company based in Cambridge (United States), founded in 2019 by Paris Panayiotopoulos and Jonathan Freeman. It operates as a Developer of novel anticoagulants for thrombosis treatment. Anthos Therapeutics has raised $250M in funding from Blackstone and Novartis, with last known valuation of $3.1B. The company has 220 active competitors, including 71 funded and 61 that have exited. Its top competitors include companies like argenx, Alexion and Halozyme.

Sectors and market segments that Anthos Therapeutics operate in

Anthos Therapeutics serves in the Life Sciences market segments.The primary business model of Anthos Therapeutics are:

Company Details

Developer of novel anticoagulants for thrombosis treatment. The company focuses on addressing unmet needs in anticoagulant therapy, particularly in areas like atrial fibrillation and cancer-associated thrombosis. Its lead product is a novel anticoagulant designed to reduce bleeding risks compared to existing therapies. Research and development efforts are centered on improving treatment options for patients at risk of thrombotic events. The company's approach is based on extensive clinical research and a deep understanding of hemostasis.

Website: anthostherapeutics.com
Email ID: *****@anthostherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Acquired

Total Funding

$250M in 1 round

Latest Funding Round

PE, Feb 28, 2019, $250M

Last Known Valuation

$3.1B as on Feb 11, 2025

Investors

Blackstone & 4 more

Ranked

46^th among 220 active competitors

Employee Count

60 as on Mar 18, 2025

Similar Companies

argenx & 265 more

Exit Details

Acquired by Novartis (Feb 11, 2025)

View Anthos Therapeutics' full profile

Anthos Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ANTHOS THERAPEUTICS, INC. CIN: 83-0933576 , United States, Active	Jun 17, 2018	-	14 (As on Dec 31, 2023)	-

Anthos Therapeutics got acquired by Novartis on Feb 11, 2025 at an acquisition amount of $*****.

Click here to take a look at Anthos Therapeutics's acquisition in detail

Anthos Therapeutics has raised a total funding of $250M over 1 round. Its latest funding round was a PE round on Feb 28, 2019 for $250M. 2 investors participated in its latest round. Anthos Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Anthos Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2019	$250M	PE	-	-	Blackstone, Novartis	-

Access funding benchmarks and valuations. Sign up today!

View details of Anthos Therapeutics's funding rounds and investors

The founders of Anthos Therapeutics are Paris Panayiotopoulos and Jonathan Freeman. Bill Meury is the CEO of Anthos Therapeutics.

Here are the details of Anthos Therapeutics' key team members:

Paris Panayiotopoulos: Co-Founder of Anthos Therapeutics.
Jonathan Freeman: Co-Founder & COO of Anthos Therapeutics.
Contact Info: 1 email address
Bill Meury: CEO of Anthos Therapeutics.
Contact Info: 2 email addresses

View details of Anthos Therapeutics's Founder profiles and Board Members

Anthos Therapeutics' employee count trend

Anthos Therapeutics has 60 employees as of Mar 25. Here is Anthos Therapeutics's employee count trend over the years:

Employee count trend for Anthos Therapeutics

Uncover Anthos Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anthos Therapeutics include argenx, Alexion and Halozyme. Here is the list of Top 10 competitors of Anthos Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
3rd	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, Third Security & 8 others	67/100
4th	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Orbimed & 9 others	67/100
5th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, SVB & 5 others	65/100
6th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	62/100
9th	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 5 others	62/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	62/100
46th	Anthos Therapeutics 2019, Cambridge (United States), Acquired	Developer of novel anticoagulants for thrombosis treatment	$250M	Novo Holdings, Nan Fung Life Sciences & 3 others	51/100